MYC and neoplasm: While bitransgenic mice in the EμEBER1.127 and EμN-myc cross on average showed a reduced latency to tumour onset compared to EμN-myc mice (median of 214 days compared to 406 days, Figure 6B), the survival curves were not found to be statistically significantly different.